Dietary mushrooms: An excellent source for nutraceuticals capable of reducing risk factors for cardiovascular disease

W. J. Tucker, Siddhartha Angadi, K. R. Martin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the developed world. Epidemiological evidence suggests that dietary intervention is an important and effective means of reducing CVD risk due to the plethora of beneficial bioactive agents present primarily in plant-based diets. Mushrooms such as shiitake (Lentinus edodes), maitake (Grifola frondosa) and oyster (Pleurotus ostreatus) in particular are rich in bioactive compounds. These compounds include eritadenine, lovastatin, beta-glucans, ergothioneine, flavonoids, ergosterols, zaragozic acids and phenolic compounds, which function as nutraceuticals via numerous mechanisms to lower CVD risk. This occurs, in part, by lowering total plasma and low-density lipoprotein (LDL) cholesterol levels, increasing bile acid excretion and hepatic LDL receptor mRNA expression and inhibiting HMG CoA reductase and squalene synthesis. Mushrooms also exert anti-inflammatory, immunomodulating, anti-coagulant, anti-hypertensive and anti-adhesive properties that collectively diminish atherosclerotic risk. Furthermore, dietary mushrooms may inhibit development of atherosclerotic plaques and purportedly reduce the overall plaque size if already present. Emerging research suggests that many of these effects not only occur at the level of molecular interaction and enzymatic inhibition but also at the level of gene expression changes. Thus, dietary mushrooms are a rich source of nutraceuticals and may be an important dietary means of reducing the risk for CVD.

Original languageEnglish (US)
Title of host publicationNutrigenomics: Application to the Development of Nutraceuticals and Cosmeceuticals
PublisherNova Science Publishers, Inc.
Pages35-53
Number of pages19
ISBN (Print)9781624170515
StatePublished - Jan 2013

Fingerprint

Agaricales
Dietary Supplements
Grifola
Cardiovascular Diseases
Ergothioneine
Shiitake Mushrooms
Squalene
Pleurotus
Hydroxymethylglutaryl CoA Reductases
Ergosterol
Lovastatin
Ostreidae
Coagulants
beta-Glucans
Molecular interactions
LDL Receptors
Atherosclerotic Plaques
Nutrition
Bile Acids and Salts
Flavonoids

Keywords

  • Bioactive agents
  • Cardiovascular disease
  • Dietary mushrooms
  • Nutraceuticals
  • Nutrigenomics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tucker, W. J., Angadi, S., & Martin, K. R. (2013). Dietary mushrooms: An excellent source for nutraceuticals capable of reducing risk factors for cardiovascular disease. In Nutrigenomics: Application to the Development of Nutraceuticals and Cosmeceuticals (pp. 35-53). Nova Science Publishers, Inc..

Dietary mushrooms : An excellent source for nutraceuticals capable of reducing risk factors for cardiovascular disease. / Tucker, W. J.; Angadi, Siddhartha; Martin, K. R.

Nutrigenomics: Application to the Development of Nutraceuticals and Cosmeceuticals. Nova Science Publishers, Inc., 2013. p. 35-53.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tucker, WJ, Angadi, S & Martin, KR 2013, Dietary mushrooms: An excellent source for nutraceuticals capable of reducing risk factors for cardiovascular disease. in Nutrigenomics: Application to the Development of Nutraceuticals and Cosmeceuticals. Nova Science Publishers, Inc., pp. 35-53.
Tucker WJ, Angadi S, Martin KR. Dietary mushrooms: An excellent source for nutraceuticals capable of reducing risk factors for cardiovascular disease. In Nutrigenomics: Application to the Development of Nutraceuticals and Cosmeceuticals. Nova Science Publishers, Inc. 2013. p. 35-53
Tucker, W. J. ; Angadi, Siddhartha ; Martin, K. R. / Dietary mushrooms : An excellent source for nutraceuticals capable of reducing risk factors for cardiovascular disease. Nutrigenomics: Application to the Development of Nutraceuticals and Cosmeceuticals. Nova Science Publishers, Inc., 2013. pp. 35-53
@inbook{e967d75826ac40808b5e5bb4348e4126,
title = "Dietary mushrooms: An excellent source for nutraceuticals capable of reducing risk factors for cardiovascular disease",
abstract = "Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the developed world. Epidemiological evidence suggests that dietary intervention is an important and effective means of reducing CVD risk due to the plethora of beneficial bioactive agents present primarily in plant-based diets. Mushrooms such as shiitake (Lentinus edodes), maitake (Grifola frondosa) and oyster (Pleurotus ostreatus) in particular are rich in bioactive compounds. These compounds include eritadenine, lovastatin, beta-glucans, ergothioneine, flavonoids, ergosterols, zaragozic acids and phenolic compounds, which function as nutraceuticals via numerous mechanisms to lower CVD risk. This occurs, in part, by lowering total plasma and low-density lipoprotein (LDL) cholesterol levels, increasing bile acid excretion and hepatic LDL receptor mRNA expression and inhibiting HMG CoA reductase and squalene synthesis. Mushrooms also exert anti-inflammatory, immunomodulating, anti-coagulant, anti-hypertensive and anti-adhesive properties that collectively diminish atherosclerotic risk. Furthermore, dietary mushrooms may inhibit development of atherosclerotic plaques and purportedly reduce the overall plaque size if already present. Emerging research suggests that many of these effects not only occur at the level of molecular interaction and enzymatic inhibition but also at the level of gene expression changes. Thus, dietary mushrooms are a rich source of nutraceuticals and may be an important dietary means of reducing the risk for CVD.",
keywords = "Bioactive agents, Cardiovascular disease, Dietary mushrooms, Nutraceuticals, Nutrigenomics",
author = "Tucker, {W. J.} and Siddhartha Angadi and Martin, {K. R.}",
year = "2013",
month = "1",
language = "English (US)",
isbn = "9781624170515",
pages = "35--53",
booktitle = "Nutrigenomics: Application to the Development of Nutraceuticals and Cosmeceuticals",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Dietary mushrooms

T2 - An excellent source for nutraceuticals capable of reducing risk factors for cardiovascular disease

AU - Tucker, W. J.

AU - Angadi, Siddhartha

AU - Martin, K. R.

PY - 2013/1

Y1 - 2013/1

N2 - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the developed world. Epidemiological evidence suggests that dietary intervention is an important and effective means of reducing CVD risk due to the plethora of beneficial bioactive agents present primarily in plant-based diets. Mushrooms such as shiitake (Lentinus edodes), maitake (Grifola frondosa) and oyster (Pleurotus ostreatus) in particular are rich in bioactive compounds. These compounds include eritadenine, lovastatin, beta-glucans, ergothioneine, flavonoids, ergosterols, zaragozic acids and phenolic compounds, which function as nutraceuticals via numerous mechanisms to lower CVD risk. This occurs, in part, by lowering total plasma and low-density lipoprotein (LDL) cholesterol levels, increasing bile acid excretion and hepatic LDL receptor mRNA expression and inhibiting HMG CoA reductase and squalene synthesis. Mushrooms also exert anti-inflammatory, immunomodulating, anti-coagulant, anti-hypertensive and anti-adhesive properties that collectively diminish atherosclerotic risk. Furthermore, dietary mushrooms may inhibit development of atherosclerotic plaques and purportedly reduce the overall plaque size if already present. Emerging research suggests that many of these effects not only occur at the level of molecular interaction and enzymatic inhibition but also at the level of gene expression changes. Thus, dietary mushrooms are a rich source of nutraceuticals and may be an important dietary means of reducing the risk for CVD.

AB - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the developed world. Epidemiological evidence suggests that dietary intervention is an important and effective means of reducing CVD risk due to the plethora of beneficial bioactive agents present primarily in plant-based diets. Mushrooms such as shiitake (Lentinus edodes), maitake (Grifola frondosa) and oyster (Pleurotus ostreatus) in particular are rich in bioactive compounds. These compounds include eritadenine, lovastatin, beta-glucans, ergothioneine, flavonoids, ergosterols, zaragozic acids and phenolic compounds, which function as nutraceuticals via numerous mechanisms to lower CVD risk. This occurs, in part, by lowering total plasma and low-density lipoprotein (LDL) cholesterol levels, increasing bile acid excretion and hepatic LDL receptor mRNA expression and inhibiting HMG CoA reductase and squalene synthesis. Mushrooms also exert anti-inflammatory, immunomodulating, anti-coagulant, anti-hypertensive and anti-adhesive properties that collectively diminish atherosclerotic risk. Furthermore, dietary mushrooms may inhibit development of atherosclerotic plaques and purportedly reduce the overall plaque size if already present. Emerging research suggests that many of these effects not only occur at the level of molecular interaction and enzymatic inhibition but also at the level of gene expression changes. Thus, dietary mushrooms are a rich source of nutraceuticals and may be an important dietary means of reducing the risk for CVD.

KW - Bioactive agents

KW - Cardiovascular disease

KW - Dietary mushrooms

KW - Nutraceuticals

KW - Nutrigenomics

UR - http://www.scopus.com/inward/record.url?scp=84895322796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895322796&partnerID=8YFLogxK

M3 - Chapter

SN - 9781624170515

SP - 35

EP - 53

BT - Nutrigenomics: Application to the Development of Nutraceuticals and Cosmeceuticals

PB - Nova Science Publishers, Inc.

ER -